pillbase.ru

REPATHA

Active substance: evolocumab

INJECTION, SOLUTION · EVOLOCUMAB 140 mg/mL

United StatesActive

Marketing holder: Amgen USA Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 2
  • Репата
    раствор для подкожного введения, 140 мг/мл, 1 мл (original in Russian, GRLS)
    ЛП-003574
    Амджен Европа Б.В.
  • Репата®
    раствор для подкожного введения, 140 мг/мл, 1 мл (original in Russian, GRLS)
    ЛП-№(010779)-(РГ-RU)
    Амджен Европа Б.В.
EU 1
  • Repatha
    Evolocumab
    EMEA/H/C/003766
    Amgen Europe B.V.
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-b8b2-703e-9a49-9256e97ce31d,01a120c5-b73b-70ba-be7d-195ae461c378;count=2 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-2b7d-7648-9e34-d5ce6ef9eead,01a1208f-0956-7bc1-8c4f-c94b5eb4e6e3,01a12092-ab17-7a62-9dcb-19cfa80274bb,01a1209c-0c27-70b1-8324-f4b517833602,01a1209e-67cc-71b7-b311-90d48217be85;count=5 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
72511-393
Registration status
Active
Dispensing
Prescription only
Route
SUBCUTANEOUS
Sources
  • product · openFDA NDC · 72511-393 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 72511-393 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 72511-393 · Verified 2026-10-09 · open in source